Amneal Pharmaceuticals, Inc.
AMRX· Nasdaq
AMRXAmneal Pharmaceuticals, Inc.
Filed Mar 1, 2021 · 10-K · 60 days after period end · 0001723128-21-000013
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 | Q4 2017 |
|---|---|---|---|---|
| Revenue | $510.03M | $397.33M | $497.53M | $293.37M |
| Net Income | -$6.83M | -$64.90M | -$20.33M | $0.00 |
| EPS Diluted | — | -$0.23 | -$0.07 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
ended Dec 31, 2020 · filed Mar 1, 2021 · 60 d after period end
